Publikation: Ebselen Improves Ischemia-Reperfusion Injury After Rat Lung Transplantation
Dateien
Datum
Autor:innen
Herausgeber:innen
ISSN der Zeitschrift
Electronic ISSN
ISBN
Bibliografische Daten
Verlag
Schriftenreihe
Auflagebezeichnung
DOI (zitierfähiger Link)
Internationale Patentnummer
Angaben zur Forschungsförderung
Projekt
Open Access-Veröffentlichung
Sammlungen
Core Facility der Universität Konstanz
Titel in einer weiteren Sprache
Publikationstyp
Publikationsstatus
Erschienen in
Zusammenfassung
The heterocyclic organic compound ebselen (2-phenyl-1,2-benizsoselenazol-3(2H)-one) is a glutathione peroxidase mimick with protective properties against oxidative injury. Ebselen also has anti-inflammatory activity, including attenuation of tumor necrosis factor release and increase of interleukin-10, as shown in vivo, in inflammatory and ischemia-reperfusion injuries, including those of the lung. This study was designed to assess its effect on severe ischemia-reperfusion injury in a model of left-sided rat lung isotransplantation. Orthotopic single left-sided lung allotransplantation (Wistar to Wistar) was performed in female rats after a total ischemic time of 18 h. In nine recipients given 500 mg/kg oral ebselen 1 h before transplantation, graft PaO2/FiO2 was improved 24 h after transplantation, as evidenced with a mean (standard deviation) PaO2 of 139 (61) mmHg vs. eight controls with 65 (33) mmHg (p = 0.009). Bronchoalveolar PMN count was reduced to approximately 50% in the ebselen group compared with controls, whereas no difference in the tumor necrosis factor content was found. We conclude that the improvement of lung function in ebselen-treated transplanted rats is mainly the result of the anti-inflammatory activity of the drug during reperfusion.
Zusammenfassung in einer weiteren Sprache
Fachgebiet (DDC)
Schlagwörter
Konferenz
Rezension
Zitieren
ISO 690
HAMACHER, Jürg, Uz STAMMBERGER, Elvira WEBER, Rudolf LUCAS, Albrecht WENDEL, 2009. Ebselen Improves Ischemia-Reperfusion Injury After Rat Lung Transplantation. In: Lung. Springer. 2009, 187(2), pp. 98-103. ISSN 0341-2040. eISSN 1432-1750. Available under: doi: 10.1007/s00408-009-9134-xBibTex
@article{Hamacher2009Ebsel-58127,
year={2009},
doi={10.1007/s00408-009-9134-x},
title={Ebselen Improves Ischemia-Reperfusion Injury After Rat Lung Transplantation},
number={2},
volume={187},
issn={0341-2040},
journal={Lung},
pages={98--103},
author={Hamacher, Jürg and Stammberger, Uz and Weber, Elvira and Lucas, Rudolf and Wendel, Albrecht}
}RDF
<rdf:RDF
xmlns:dcterms="http://purl.org/dc/terms/"
xmlns:dc="http://purl.org/dc/elements/1.1/"
xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
xmlns:bibo="http://purl.org/ontology/bibo/"
xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#"
xmlns:foaf="http://xmlns.com/foaf/0.1/"
xmlns:void="http://rdfs.org/ns/void#"
xmlns:xsd="http://www.w3.org/2001/XMLSchema#" >
<rdf:Description rdf:about="https://kops.uni-konstanz.de/server/rdf/resource/123456789/58127">
<bibo:uri rdf:resource="https://kops.uni-konstanz.de/handle/123456789/58127"/>
<dcterms:abstract xml:lang="eng">The heterocyclic organic compound ebselen (2-phenyl-1,2-benizsoselenazol-3(2H)-one) is a glutathione peroxidase mimick with protective properties against oxidative injury. Ebselen also has anti-inflammatory activity, including attenuation of tumor necrosis factor release and increase of interleukin-10, as shown in vivo, in inflammatory and ischemia-reperfusion injuries, including those of the lung. This study was designed to assess its effect on severe ischemia-reperfusion injury in a model of left-sided rat lung isotransplantation. Orthotopic single left-sided lung allotransplantation (Wistar to Wistar) was performed in female rats after a total ischemic time of 18 h. In nine recipients given 500 mg/kg oral ebselen 1 h before transplantation, graft PaO2/FiO2 was improved 24 h after transplantation, as evidenced with a mean (standard deviation) PaO2 of 139 (61) mmHg vs. eight controls with 65 (33) mmHg (p = 0.009). Bronchoalveolar PMN count was reduced to approximately 50% in the ebselen group compared with controls, whereas no difference in the tumor necrosis factor content was found. We conclude that the improvement of lung function in ebselen-treated transplanted rats is mainly the result of the anti-inflammatory activity of the drug during reperfusion.</dcterms:abstract>
<foaf:homepage rdf:resource="http://localhost:8080/"/>
<dc:creator>Hamacher, Jürg</dc:creator>
<dcterms:title>Ebselen Improves Ischemia-Reperfusion Injury After Rat Lung Transplantation</dcterms:title>
<dc:contributor>Weber, Elvira</dc:contributor>
<dc:language>eng</dc:language>
<dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
<dc:contributor>Stammberger, Uz</dc:contributor>
<dc:creator>Weber, Elvira</dc:creator>
<dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
<dc:creator>Stammberger, Uz</dc:creator>
<dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2022-07-22T07:32:23Z</dc:date>
<dc:creator>Wendel, Albrecht</dc:creator>
<dc:contributor>Lucas, Rudolf</dc:contributor>
<dc:creator>Lucas, Rudolf</dc:creator>
<dc:contributor>Wendel, Albrecht</dc:contributor>
<void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/>
<dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2022-07-22T07:32:23Z</dcterms:available>
<dcterms:issued>2009</dcterms:issued>
<dc:contributor>Hamacher, Jürg</dc:contributor>
</rdf:Description>
</rdf:RDF>
